Drug treatment of acute ischemic stroke

American Journal of Cardiovascular Drugs

Volumn 13, Issue 1, 2013, Pages 57-69

  Bansal, Sameer ^a   Sangha, Kiranpal S ^b   Khatri, Pooja ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; ANTIPYRETIC AGENT; APIXABAN; CERTOPARIN; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; DANAPAROID; DESMOTEPLASE; ENALAPRILAT; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; INSULIN; LABETALOL; LISINOPRIL; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NICARDIPINE; NIFEDIPINE; PLACEBO; RIVAROXABAN; TENECTEPLASE; TICAGRELOR; TINZAPARIN; TIROFIBAN; UNINDEXED DRUG; WARFARIN;

ANGIONEUROTIC EDEMA; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONFORMATIONAL TRANSITION; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMERGENCY WARD; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INJURY; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL HYPERTENSION; LONG TERM CARE; LOW DRUG DOSE; MECHANICAL THROMBECTOMY; MIDDLE CEREBRAL ARTERY; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NEUROPROTECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PRIORITY JOURNAL; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RISK REDUCTION; SECONDARY PREVENTION; SEIZURE; SYSTOLIC BLOOD PRESSURE; THERAPY; THROMBOCYTE AGGREGATION; TISSUE OXYGENATION; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84874085601     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0007-6     Document Type: Article

References (94)

1. American Heart Association. Heart disease and stroke statistics-2011 update. Circulation. 2011;123:e18-209.
2. Grotta J, Pasteur W, Khwaja G, et al. Elective intubation for neurologic deterioration after stroke. Neurology. 1995;45:640-4.
3. Adams Jr HP. Management of patients with acute ischaemic stroke. Drugs 1997;54(Suppl. 3):60-9; discussion 69-70.
4. Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276:1328-31.
5. Lansberg MG, Albers GW, Wijman CAC. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of risk factors. Cerebrovasc Dis. 2007;24:1-10.
6. Kleindorfer DO, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke a population based study. Stroke. 2004;35:e27-9.
7. Bruno A, Biller J, Adams HP Jr, et al. Acute blood glucose level and outcome from ischemic stroke: Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999;52:280-4.
8. Davalos A, Castillo J. Potential mechanisms of worsening. Cerebrovasc Dis. 1997;7(Suppl. 5):19-24.
9. Johnson KC. SHINE Trial (NCT 01369069). http://www.clinicaltrials.gov. Accessed 5-17-2012.
10. Jorgensen HS, Reith J, Nakayama H, et al. What determines good recovery in patients with the most severe strokes? The Copenhagen Stroke Study. Stroke. 1999;30:2008-12.
11. Lindsberg PJ, Roine RO, Tatlisumak T, et al. The future of stroke treatment. Neurol Clin. 2000;18:495-510.
12. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic stroke: A Guideline for Health Care Professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-76.
13. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with Alteplase 3 to 4.5 hours after Acute Ischemic Stroke. N Engl J Med. 2008;359:1317-29.
14. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-703.
15. Alteplase Monograph Class: Thrombolytic Agents. AHFS Drug Information. American Society of Health-System Pharmacists, Inc, 7272 Wisconsin Avenue, Betheda, Maryland 20814.
16. Adams HP, del Zoppo Gregory, Albers MJ, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: American Academy of Neurology affirms the value of this guideline as an Quality of Care Outcomes in Research Interdisciplinary Working Groups: The Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Guideline from the American Heart Association/ American Stroke Association educational tool for neurologists. Stroke 2007;38:1655-711.
17. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for Acute ischemic stroke. N Engl J Med 1995;333:1581-7.
18. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-25.
19. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1302-9.
20. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-26.
21. Del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4-11.
22. Lewandowski C, Frankel M, Tomsick T, et al. Combined intravenous and intra-arterial r-tPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598-605.
23. Bose A, Henkes K, Alfke W, et al. The penumbra system: a mechanical device for the treatment of acute stroke due to thromboembolism. Am J Neuroradiol. 2008;29:1409-13.
24. Flaherty ML, Woo D, Kissela B, et al. Combined IV and intraarterial thrombolysis for acute ischemic stroke. Neurology. 2005;64:386-8.
25. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke. 2004;35:904-11.
26. Zaidat OO, Suarez JI, Santillan C, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke. 2002;33:1821-6.
27. The IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127-35.
28. Lee KY, Kim DI, Kim SH, et al. Sequential combination of intravenous recombinant tissue plasminogen activator and intraarterial urokinase in acute ischemic stroke. Am J Neuroradiol. 2004;25:1470-5.
29. Khatri P, Hill MD, Palesch YY, et al. for the IMS III Investigators, Methodology of the Interventional Management of Stroke (IMS) III Trial. Int J Stroke 2008;3:130-7.
30. The Therapy Trial: The Randomized Concurrent trial to assess the Penumbra System's Safety and Effectiveness in the treatment of Acute Stroke (NCT 01429350). http://www.clinicaltrials.gov. Accessed 5-31-2012.
31. Donnan GA, Hommel M, Davis SM, et al. Steering Committees of the ASK and MAST-E Trials, Australian Streptokinase Trial; Streptokinase in acute ischaemic stroke. Lancet 1995;346:56. Comment.
32. Hommel M, Boissel JP, Cornu C, et al., MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995;345:57. Comment.
33. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
34. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
35. Pasons M, Spratt N, Bivard A, et al. A randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke. N Engl J Med 2012;366:1099-10.
36. Clarke Haley E, Thompson JLP, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41:707-11.
37. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, doubleblind, placebo-controlled study. Lancet Neurol. 2009;8:141-50.
38. Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4). (NCT 00856661) http://www.clinicaltrials.gov. Accessed 6-14-2012.
39. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-81.
40. Saxena R, Lewis S, Berge E, et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 2001;32:2333-7.
41. Roden-Jullig A, Britton M. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J Intern Med. 2000;248:287-91.
42. Camerlingo M, Salvi P, Belloni G, et al. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005;36:2415-20.
43. Chamorro A, Busse O, Obach V, et al. RAPID Investigators. The rapid anticoagulation prevents ischemic damage study in acute stroke: final results from the writing committee. Cerebrovasc Dis. 2005;19:402-4.
44. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333:1588-93.
45. Diener HC, Ringelstein EB, von Kummer R, et al. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Stroke. 2001;32:22-9.
46. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279:1265-72.
47. Adams HP Jr, Bendixen BH, Leira E, et al. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999;53:122-5.
48. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-8.
49. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III Study: rationale, design and patient features. J Stroke Cerebrovasc Dis. 1997;6:341-53.
50. European Atrial Fibrillation Trial Study Group. European Atrial Fibrillation Trial: secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke. Lancet. 1993;342:1255-62.
51. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
52. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285-95.
53. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
54. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9.
55. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
56. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: a randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-9.
57. Chen ZM, Collins R, Peto R, et al. Interpretation of IST and CAST stroke trials. Lancet. 1997;350:444. Letter.
58. Gent M, Hampton JR, Roberts RS, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39.
59. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331-7.
60. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2005;150:e1-401.
61. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13.
62. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-73.
63. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-51.
64. Pancioli A, Broderick JP, Brott T, et al. for the CLEAR Trial Investigators. The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (The CLEAR Stroke Trial). Stroke. 2008;39(12):3268-76.
65. Siebler M, Hennerici MG, Schneider D, et al. Safety of tirofiban in acute ischemic stroke the SaTIS trial. Stroke. 2011;42:2388-92.
66. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
67. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.
68. Janardhan V, Qureshi AI. Mechanisms of ischemic brain injury. Curr Cardiol Rep. 2004;6:117-23.
69. Maramattom BV, Bahn MM, Wijdicks EF. Which patient fares worse after early deterioration due to swelling from hemispheric stroke? Neurology. 2004;63:2142-5.
70. Heinsius T, Bogousslavsky J, Van Melle G. Large infarcts in the middle cerebral artery territory: etiology and outcome patterns. Neurology. 1998;50:341-50.
71. Manno EM, Nichols DA, Fulgham JR, et al. Computed tomographic determinants of neurologic deterioration in patients with large middle cerebral artery infarctions. Mayo Clin Proc. 2003;78:156-60.
72. Wijdicks EF, Diringer MN. Middle cerebral artery territory infarction and early brain swelling: progression and effect of age on outcome. Mayo Clin Proc. 1998;73:829-36.
73. Qureshi AI, Suarez JI, Yahia AM, et al. Timing of neurologic deterioration in massive middle cerebral artery infarction: a multicenter review. Crit Care Med. 2003;31:272-7.
74. Ropper AH, Shafran B. Brain edema after stroke: clinical syndrome and intracranial pressure. Arch Neurol. 1984;41:26-9.
75. Frank JI. Large hemispheric infarction, deterioration, and intracranial pressure. Neurology. 1995;45:1286-90.
76. Marshall LF, Smith RW, Rauscher LA, et al. Mannitol dose requirements in brain-injured patients. J Neurosurg. 1978;48:169-72.
77. Koenig MA, Bryan M, Lewin JL, et al. Reversal of transtentorial herniation with hypertonic saline. Neurology. 2008;70:1023-9.
78. Crowell RM. STA-MCA bypass for acute focal cerebral ischemia. In: Schmiedek P, editor. Microsurgery for stroke. New York: Springer; 1977. p. 244-50.
79. Delashaw JB, Broaddus WC, Kassell NF, et al. Treatment of right hemispheric cerebral infarction by hemicraniectomy. Stroke. 1990;21:874-81.
80. Hacke W, Schwab S, Horn M, et al. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53:309-15.
81. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215-22.
82. Jüttler E, Bösel J, Amiri H, et al. for the DESTINY II Study Group. DESTINY II: DEcompressive Surgery for the Treatment of malignant INfarction of the middle cerebral arterY II. Int J Stroke. 2011;6:79-86.
83. Heo JH, Han SW, Lee SK. Free radicals as triggers of brain edema formation after stroke. Free Radic Biol Med. 2005;39:51-70.
84. Szaflarski P, Rackley AY, Kleindorfer DO, et al. Incidence of seizures in the acute phase of stroke: a population based study. Epilepsia. 2008;49:974-81.
85. Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Neurology. 1995;45:865-71.
86. Goldstein LB. Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. Neurology. 1995;45:865-71.
87. Hofmeijer J, van der Worp HB, Kappelle LJ. Treatment of space occupying cerebral infarction. Crit Care Med. 2003;31:617-25.
88. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:957-60.
89. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke. 1994;25:1755-9.
90. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT Study: a randomized controlled trial: Stroke Treatment with Ancrod Trial. JAMA. 2000;283:2395-403.
91. Bogousslavsky J, Regli F. Anticoagulant-induced intracerebral bleeding in brain ischemia: evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke. Acta Neurol Scand. 1985;71:464-71.
92. Hill MD, Barber PA, Takahashi J, et al. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. CMAJ. 2000;162(9):1281-4.
93. Rudolf J, Grond M, Price WS, et al. Evidence of anaphylaxis after alteplase infusion. Stroke. 1999;5:1142-3.
94. Sangha K, Adeoye O, Kleindorfer D, et al. Alteplase Induced Systemic Fibrinolytic Reaction: A case series and review of the literature. 2011 Neurocritical Care Society Annual Meeting, Montreal, QC, Canada. Poster Presentation.